{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T16:03:57Z","timestamp":1766678637113,"version":"3.37.3"},"reference-count":10,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.3899\/jrheum.200484","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T16:21:24Z","timestamp":1602778884000},"page":"304-305","source":"Crossref","is-referenced-by-count":9,"title":["Upfront Combination Therapy With Rituximab and Mycophenolate Mofetil for Progressive Systemic Sclerosis"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9137-2322","authenticated-orcid":false,"given":"Doron","family":"Rimar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itzhak","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gleb","family":"Slobodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2022062114101488000_48.2.304.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211912"},{"key":"2022062114101488000_48.2.304.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2022062114101488000_48.2.304.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213708"},{"key":"2022062114101488000_48.2.304.4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med."},{"key":"2022062114101488000_48.2.304.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3"},{"key":"2022062114101488000_48.2.304.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368"},{"key":"2022062114101488000_48.2.304.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703327"},{"key":"2022062114101488000_48.2.304.8","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1229::AID-ART6>3.0.CO;2-W"},{"key":"2022062114101488000_48.2.304.9","first-page":"142","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study","volume":"36","author":"Fraticelli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114101488000_48.2.304.10","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30010-2","article-title":"The future of treatment in systemic sclerosis: can we design better trials?","volume":"2","author":"Pope","year":"2020","journal-title":"Lancet Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.200484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:12:16Z","timestamp":1655845936000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.200484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.3899\/jrheum.200484"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.200484","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}